نتائج البحث - "Boceprevir"

51

Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C

المؤلفون: Chriss Homan, Philip R. Spradling, Stephen Livingston, Brian J. McMahon, Lisa Townshend-Bulson, Dana J. T. Bruden, Brenna C. Simons, James E. Gove, Julia Plotnik

المساهمون: Centers for Disease Control and Prevention

المصدر: International Journal of Circumpolar Health; Vol 75 (2016)
International Journal of Circumpolar Health
International Journal of Circumpolar Health, Vol 75, Iss 0, Pp 1-8 (2016)

مصطلحات موضوعية: Male, Health (social science), Epidemiology, Hepacivirus, medicine.disease_cause, Gastroenterology, Polyethylene Glycols, Telaprevir, chemistry.chemical_compound, Pegylated interferon, discontinuation, indigenous population, longitudinal study, sustained virologic response, 0302 clinical medicine, Pegylated interferon, Interferon, Original Research Article, Longitudinal Studies, 030212 general & internal medicine, education.field_of_study, sustained virologic response, longitudinal study, virus diseases, General Medicine, Middle Aged, Alaskan Natives, Recombinant Proteins, 3. Good health, Treatment Outcome, Drug Therapy, Combination, Female, 030211 gastroenterology & hepatology, medicine.drug, Adult, medicine.medical_specialty, lcsh:Arctic medicine. Tropical medicine, clinical investigation, infectious disease, lcsh:RC955-962, Hepatitis C virus, Population, Alpha interferon, viral hepatitis, Antiviral Agents, Risk Assessment, 03 medical and health sciences, Boceprevir, Internal medicine, Ribavirin, medicine, Humans, pegylated interferon, education, Aged, business.industry, Public Health, Environmental and Occupational Health, Interferon-alpha, Hepatitis C, Chronic, indigenous population, digestive system diseases, chemistry, Immunology, Indians, North American, business, Alaska, discontinuation, Follow-Up Studies

وصف الملف: application/pdf; text/html; application/epub+zip; application/xml

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::022dccf02aa83a6629b95c2c834e1ad9Test
http://www.circumpolarhealthjournal.net/index.php/ijch/article/view/30696Test

52

Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1

المؤلفون: Daniel Grimm, Tim Zimmermann, Dietrich Hueppe, Peter Buggisch, Peter R. Galle, H Pfeiffer-Vornkahl, Ulrich Alshuth, Stefan Mauss

المصدر: Web of Science

مصطلحات موضوعية: Male, Time Factors, 030508 substance abuse, Hepacivirus, medicine.disease_cause, Gastroenterology, Telaprevir, Polyethylene Glycols, chemistry.chemical_compound, 0302 clinical medicine, Risk Factors, Germany, Odds Ratio, Aged, 80 and over, Smoking, Hepatitis C, Middle Aged, Viral Load, Recombinant Proteins, Treatment Outcome, Drug Therapy, Combination, Female, 0305 other medical science, Viral load, Oligopeptides, medicine.drug, Adult, medicine.medical_specialty, Adolescent, Genotype, Proline, Hepatitis C virus, Alpha interferon, Antiviral Agents, 03 medical and health sciences, Young Adult, Boceprevir, Internal medicine, Ribavirin, medicine, Humans, Protease inhibitor (pharmacology), Protease Inhibitors, Aged, business.industry, Interferon-alpha, medicine.disease, Virology, 030227 psychiatry, Logistic Models, chemistry, Multivariate Analysis, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b75f74390a18c74d4c779724fa14a32Test
https://pubmed.ncbi.nlm.nih.gov/27014750Test

53

Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin

المؤلفون: Ira M. Jacobson, Fred Poordad, Jean-Pierre Bronowicki, Navdeep Boparai, Stefan Zeuzem, Margaret Burroughs, Lisa D. Pedicone, Keith Gottesdiener, Clifford A. Brass, Patrick Marcellin, Mark J. DiNubile, Mark S. Sulkowski, Janice K. Albrecht, Rafael Esteban, Savino Bruno, W. Deng

المصدر: Hepatology. 56:567-575

مصطلحات موضوعية: medicine.medical_specialty, Databases, Factual, Genotype, Proline, Combination therapy, Hepacivirus, Interferon alpha-2, Antiviral Agents, Gastroenterology, Polyethylene Glycols, chemistry.chemical_compound, Pharmacotherapy, Internal medicine, Boceprevir, Ribavirin, medicine, Humans, Treatment Failure, Randomized Controlled Trials as Topic, Retrospective Studies, Hepatology, business.industry, Interferon-alpha, virus diseases, Hepatitis C, Hepatitis C, Chronic, medicine.disease, Recombinant Proteins, digestive system diseases, Discontinuation, Surgery, Clinical trial, Clinical Trials, Phase III as Topic, chemistry, RNA, Viral, Drug Therapy, Combination, Drug Monitoring, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c13bc73f9ff65a11aa89bd0ae18fb93fTest
https://doi.org/10.1002/hep.25865Test

54

Recent Advances in the Treatment of HIV/HBV and HIV/HCV Co-Infection

المؤلفون: Masgala, Aikaterini, Bonovas, Stefanos, Nikolopoulos, Georgios K.

المساهمون: Nikolopoulos, Georgios K.[0000-0002-3307-0246], Bonovas, Stefanos [0000-0001-6102-6579]

المصدر: Mini-Reviews in Medicinal Chemistry

مصطلحات موضوعية: Virus replication, Myopathy, HIV Infections, Hepacivirus, Molecular weight, Telaprevir, Hiv infections, Disease management, Drug Discovery, Coughing, Hbv, Emtricitabine, Adefovir dipivoxil, Drug safety, Highly active, Cell proliferation, Boceprevir, Coinfection, Headache, virus diseases, Lamivudine, General Medicine, Entecavir, Dna synthesis, Co-infection, Tenofovir disoproxil, Hcv, Human, Diarrhea, Insomnia, Efavirenz plus emtricitabine plus tenofovir disoproxil, Bone marrow suppression, Vomiting, Kidney failure, Interferon alpha-2, Dysgeusia, Antiviral Agents, Article, Drug Administration Schedule, Human immunodeficiency virus infection, Asunaprevir, Humans, Disease exacerbation, Peginterferon, Antiretrovirus agent, Pharmacology, Src homology domain, Hiv-1, Abnormal dreaming, Myalgia, medicine.disease, Virology, Influenza, digestive system diseases, Pancreatitis, chemistry, Drug resistance, Asthenia, HIV-1, Inosinate dehydrogenase, Hemolytic anemia, Gene expression, viruses, Skin manifestation, Hepatitis b, medicine.disease_cause, Hepatitis c, chemistry.chemical_compound, Hyperpigmentation, Cd4 lymphocyte count, Antiretroviral Therapy, Highly Active, Mixed infection, Viral, Nephrotoxicity, Fatigue, Chronic hepatitis, Drug tolerability, Drug withdrawal, Recombinant proteins, Drugs, Disease Management, Anemia, Nausea, Emtricitabine plus tenofovir disoproxil, Human immunodeficiency virus infected patient, Hepatitis C, Hepatitis B, Rna directed dna polymerase, Recombinant Proteins, Antiretroviral therapy, Drug sensitivity, medicine.drug, Hepatitis B virus, Fever, Alpha2b interferon, Hepatitis C virus, Peginterferon alpha2a, Peginterferon alpha2b, Bone marrow toxicity, Dizziness, Hypertransaminasemia, Daclatasvir, Highly active antiretroviral therapy, Ribavirin, Drug Resistance, Viral, medicine, Telbivudine, business.industry, Hepatitis b virus, Drug administration schedule, Hiv, Lamivudine plus tenofovir disoproxil, Interferon-alpha, Mental disease, Treatment, Antiviral agents, business, Janus kinase

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::651b66c19cf628a2932ac5b29c9acd74Test
https://doi.org/10.2174/138955712800959062Test

55

Renal impairment in patients with chronic hepatitis C treated with first generation protease inhibitors

المؤلفون: Dorota Kozielewicz, Kornelia Karwowska, Magdalena Wietlicka-Piszcz, Dorota Dybowska

المصدر: Expert opinion on drug safety. 14(12)

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::977d52228a8ce6e6959334e34d3989b6Test
https://pubmed.ncbi.nlm.nih.gov/26513231Test

56

Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature

المؤلفون: Paul Y. Kwo, Maaz B. Badshah

المصدر: Current Gastroenterology Reports. 17

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14aaf9bff638134649937acf38cb04c2Test
https://doi.org/10.1007/s11894-015-0462-0Test

57

Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen – The ANRS CO20-CUPIC study

المؤلفون: Fabrice Carrat, Fabien Zoulim, Dominique Larrey, Lawrence Serfaty, Christophe Hézode, Hélène Fontaine, Jean-Pierre Zarski, Véronique Loustaud-Ratti, François Bailly, Cécilie Dufour, Pierre Pradat, Jean-Pierre Bronowicki, Victor Virlogeux, Marc Bourlière, Sophie Metivier, Laurent Alric, Didier Samuel

المساهمون: Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d'Hépatologie [Hôpital de la Croix-Rousse - HCL], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), École normale supérieure de Lyon (ENS de Lyon), Epidémiologie, Systèmes d'Information, Modélisation, Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service de bactériologie, virologie, hygiène [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Pharmacochimie et Biologie pour le Développement (PHARMA-DEV), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Centre hépato-biliaire (CHB), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'hépatologie et de gastroentérologie [Hôpital Saint-Joseph - Marseille], Aix Marseille Université (AMU)-Hôpital Saint-Joseph [Marseille], Pôle Maladies de l'appareil digestif [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Universitaire [Grenoble] (CHU), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Dupuytren [CHU Limoges], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), École normale supérieure - Lyon (ENS Lyon), Service d'hépatologie, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-CHU Saint-Eloi, Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC), Service d'hépato-gastro-entérologie, Assistance Publique - Hôpitaux de Marseille (APHM), Service de Gastro-entérologie - Hépatologie [Purpan], CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Clinique Universitaire d'Hépato-Gastroentérologie, CHU Grenoble, Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Dupuytren, Service d'hépatologie [Saint-Antoine], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Service d'hépatologie [CHU Saint-Antoine], Centre de Recherche en Cancérologie de Lyon (CRCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Antoine [APHP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Pierre et Marie Curie - Paris 6 (UPMC), Université de Lorraine (UL)-Institut National de la Santé et de la Recherche Médicale (INSERM)

المصدر: Clinics and Research in Hepatology and Gastroenterology
Clinics and Research in Hepatology and Gastroenterology, 2015, 39 (4), pp.443-450. ⟨10.1016/j.clinre.2014.12.007⟩
Clinics and Research in Hepatology and Gastroenterology, Elsevier, 2015, 39 (4), pp.443-450. ⟨10.1016/j.clinre.2014.12.007⟩

مصطلحات موضوعية: Liver Cirrhosis, Male, Interferon-alpha / therapeutic use, [SDV]Life Sciences [q-bio], Hepacivirus, medicine.disease_cause, Gastroenterology, Telaprevir, Polyethylene Glycols, chemistry.chemical_compound, Prospective Studies, Hepacivirus / metabolism, RNA / metabolism, Hepatitis C, Middle Aged, Viral Load, Recombinant Proteins, 3. Good health, Combination, Drug Therapy, Combination, Female, Viral load, Oligopeptides, Hepacivirus / genetics, medicine.drug, medicine.medical_specialty, Proline, Ribavirin / therapeutic use, Hepatitis C virus, Polyethylene Glycols / therapeutic use, Antiviral Agents / therapeutic use, Liver Cirrhosis / drug therapy, Antiviral Agents, Liver Cirrhosis / virology Male, Pharmacotherapy, Drug Therapy, Proline / therapeutic use, Internal medicine, Boceprevir, Ribavirin, medicine, Humans, Protease Inhibitors, Recombinant Proteins / therapeutic use, Proline / analogs & derivatives, Chronic / drug therapy, Hepatology, business.industry, Interferon-alpha, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Hepatitis C, Chronic, medicine.disease, Virology, Oligopeptides / therapeutic use, Regimen, chemistry, RNA, Protease Inhibitors / therapeutic use, business